Retatrutide
A triple agonist with the largest weight-loss numbers ever recorded in an obesity trial — and no approval, no licensed supply, and no long-term data.
Compounds
One entry per compound: what the trials actually found, what remains unknown, and the grade behind each claim. Entries carry no dosing schedules.